In 2016 the EMA has launched the PRIority MEdicines (PRIME) scheme to foster development of medicines with major public health interest and accelerate the regulatory pathway.

The main goal of the PRIME scheme is to facilitate the generation of robust data supporting the compliance to regulatory requirements and identifying emerging issues in the development.

This program applies to medicinal products that target an unmet medical need, so they can reach patients earlier and may significantly improve their quality of life.

Want to learn more about the eligibility criteria and the procedure for the PRIME scheme? Don’t miss the next ProductLife Group x Zwiers Regulatory Consultancy BV Webinar!

Alessia Cipriani
Regulatory Affairs Expert

Register to our news and events

Go to our Events to register
Go to our News to get insights

Prime Scheme – A tailored development